Literature DB >> 22102558

MR spectroscopy in schizophrenia.

John D Port1, Nivedita Agarwal.   

Abstract

The purpose of this study is to review the MR spectroscopic literature regarding schizophrenia. However, as there are over 250 primary MRS articles and dozens of MRS review articles on the subject already, this study will take a different approach. First, the clinical features of schizophrenia will be described. The background neuroanatomy and biochemistry relevant to schizophrenia will be reviewed, as many readers of this journal are unlikely to be familiar with these fields. A current model of the abnormal neural circuitry in schizophrenia will be presented, and predictions extrapolated about relevant metabolite changes over time. Finally, the existing MRS literature will be reviewed in the context of our existing anatomical and chemical knowledge, and future MRS research directions will be elaborated.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102558     DOI: 10.1002/jmri.22787

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  13 in total

Review 1.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

Review 2.  Multimodal functional and structural imaging investigations in psychosis research.

Authors:  C Christoph Schultz; Paolo Fusar-Poli; Gerd Wagner; Kathrin Koch; Claudia Schachtzabel; Oliver Gruber; Heinrich Sauer; Ralf G M Schlösser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-02       Impact factor: 5.270

Review 3.  Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.

Authors:  Moonnoh R Lee; Aleksandar Denic; David J Hinton; Prasanna K Mishra; Doo-Sup Choi; Istvan Pirko; Moses Rodriguez; Slobodan I Macura
Journal:  Bioanalysis       Date:  2012-07       Impact factor: 2.681

4.  Brain metabolite changes in subcortical regions after exposure to cuprizone for 6 weeks: potential implications for schizophrenia.

Authors:  Gen Yan; Yinghua Xuan; Zhuozhi Dai; Zhiwei Shen; Guishan Zhang; Haiyun Xu; Renhua Wu
Journal:  Neurochem Res       Date:  2014-10-28       Impact factor: 3.996

5.  Relationship of auditory electrophysiological responses to magnetic resonance spectroscopy metabolites in Early Phase Psychosis.

Authors:  Lisa A Bartolomeo; Andrew M Wright; Ruoyun E Ma; Tom A Hummer; Michael M Francis; Andrew C Visco; Nicole F Mehdiyoun; Amanda R Bolbecker; William P Hetrick; Ulrike Dydak; John Barnard; Brian F O'Donnell; Alan Breier
Journal:  Int J Psychophysiol       Date:  2019-05-23       Impact factor: 2.997

Review 6.  Translating the MAM model of psychosis to humans.

Authors:  Gemma Modinos; Paul Allen; Anthony A Grace; Philip McGuire
Journal:  Trends Neurosci       Date:  2014-12-30       Impact factor: 13.837

Review 7.  Neuroimaging for psychotherapy research: current trends.

Authors:  Carol P Weingarten; Timothy J Strauman
Journal:  Psychother Res       Date:  2014-02-17

8.  Preliminary Findings Associate Hippocampal 1H-MR Spectroscopic Metabolite Concentrations with Psychotic and Manic Symptoms in Patients with Schizophrenia.

Authors:  D Malaspina; E Lotan; H Rusinek; S A Perez; J Walsh-Messinger; T M Kranz; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2020-11-12       Impact factor: 3.825

9.  Neuroanatomical changes in people with high schizotypy: relationship to glutamate levels.

Authors:  Gemma Modinos; Alice Egerton; Anna McLaughlin; Katrina McMullen; Veena Kumari; David J Lythgoe; Gareth J Barker; André Aleman; Steve C R Williams
Journal:  Psychol Med       Date:  2017-12-04       Impact factor: 7.723

10.  Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia.

Authors:  Liv E Falkenberg; René Westerhausen; Alexander R Craven; Erik Johnsen; Rune A Kroken; Else-Marie L Berg; Karsten Specht; Kenneth Hugdahl
Journal:  Neuroimage Clin       Date:  2014-04-02       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.